Serum IL-10 levels in HIV-positive subjects: Correlation with CDC stages

F. Ameglio, P. Cordiali Fei, M. Solmone, C. Bonifati, G. Prignano, A. Giglio, F. Caprilli, G. Gentili, M. R. Capobianchi

Research output: Contribution to journalArticle

Abstract

HIV-1 infection and the HIV gpl20 have been shown to induce an IL-10 increase in cultured peripheral blood mononuclear cells. Furthermore, the expression of this cytokine has been reported to increase in lymphnodes of infected patients along the disease course, and a shift from the TH-1 towards the TH-0/TH-2 phenotypes (with subsequent IL-10 release) has been hypothesized to underly AIDS progression. In this study the serum IL-10 levels found in 30 HIV-negative controls and in 65 HIV-positive patients, untreated with AZT and negative for HBsAg and HCV-Ab have been compared, using a commercial, competitive ELISA method based on a polyclonal anti-IL-10 serum. With this test, HIV-positive sera showed IL-10 levels significantly higher than those found in the controls. In addition the IL-10 levels progressively increased in the subsequent CDC stages, without further changes from the stage III to the stage IV. Accordingly, patients evaluated two times in CDC stage II with a time interval of at least one year, showed significant IL-10 increases, even more pronounced when the same patients passed from CDC stage II to stage III. Furthermore, a significant, negative correlation was observed between the circulating IL-10 levels and the patients' CD4/CD8 ratios. These data may be important from a clinical point of view since IL-10 monitoring could be considered as a surrogate marker for evaluating the disease progression. In addition, several immunological abnormalities present in HIV positive patients, such as the monocyte/macrophage impairment and the hypergammaglobulinemia could be related to the enhanced IL-10 expression.

Original languageEnglish
Pages (from-to)48-52
Number of pages5
JournalJournal of Biological Regulators and Homeostatic Agents
Volume8
Issue number2
Publication statusPublished - 1994

Fingerprint

Centers for Disease Control and Prevention (U.S.)
interleukin-10
Interleukin-10
HIV
Serum
disease course
Hypergammaglobulinemia
CD4-CD8 Ratio
Hepatitis B Surface Antigens
mononuclear leukocytes
Human immunodeficiency virus 1
monocytes
HIV Infections
lymph nodes
Disease Progression
HIV-1
Monocytes
Blood Cells
Acquired Immunodeficiency Syndrome
macrophages

Keywords

  • CDC stages
  • HIV
  • IL-10
  • serum
  • TH-0
  • TH-1
  • TH-2

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)

Cite this

Serum IL-10 levels in HIV-positive subjects : Correlation with CDC stages. / Ameglio, F.; Cordiali Fei, P.; Solmone, M.; Bonifati, C.; Prignano, G.; Giglio, A.; Caprilli, F.; Gentili, G.; Capobianchi, M. R.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 8, No. 2, 1994, p. 48-52.

Research output: Contribution to journalArticle

@article{288026ae577e48ad952c967faabd9f7e,
title = "Serum IL-10 levels in HIV-positive subjects: Correlation with CDC stages",
abstract = "HIV-1 infection and the HIV gpl20 have been shown to induce an IL-10 increase in cultured peripheral blood mononuclear cells. Furthermore, the expression of this cytokine has been reported to increase in lymphnodes of infected patients along the disease course, and a shift from the TH-1 towards the TH-0/TH-2 phenotypes (with subsequent IL-10 release) has been hypothesized to underly AIDS progression. In this study the serum IL-10 levels found in 30 HIV-negative controls and in 65 HIV-positive patients, untreated with AZT and negative for HBsAg and HCV-Ab have been compared, using a commercial, competitive ELISA method based on a polyclonal anti-IL-10 serum. With this test, HIV-positive sera showed IL-10 levels significantly higher than those found in the controls. In addition the IL-10 levels progressively increased in the subsequent CDC stages, without further changes from the stage III to the stage IV. Accordingly, patients evaluated two times in CDC stage II with a time interval of at least one year, showed significant IL-10 increases, even more pronounced when the same patients passed from CDC stage II to stage III. Furthermore, a significant, negative correlation was observed between the circulating IL-10 levels and the patients' CD4/CD8 ratios. These data may be important from a clinical point of view since IL-10 monitoring could be considered as a surrogate marker for evaluating the disease progression. In addition, several immunological abnormalities present in HIV positive patients, such as the monocyte/macrophage impairment and the hypergammaglobulinemia could be related to the enhanced IL-10 expression.",
keywords = "CDC stages, HIV, IL-10, serum, TH-0, TH-1, TH-2",
author = "F. Ameglio and {Cordiali Fei}, P. and M. Solmone and C. Bonifati and G. Prignano and A. Giglio and F. Caprilli and G. Gentili and Capobianchi, {M. R.}",
year = "1994",
language = "English",
volume = "8",
pages = "48--52",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "2",

}

TY - JOUR

T1 - Serum IL-10 levels in HIV-positive subjects

T2 - Correlation with CDC stages

AU - Ameglio, F.

AU - Cordiali Fei, P.

AU - Solmone, M.

AU - Bonifati, C.

AU - Prignano, G.

AU - Giglio, A.

AU - Caprilli, F.

AU - Gentili, G.

AU - Capobianchi, M. R.

PY - 1994

Y1 - 1994

N2 - HIV-1 infection and the HIV gpl20 have been shown to induce an IL-10 increase in cultured peripheral blood mononuclear cells. Furthermore, the expression of this cytokine has been reported to increase in lymphnodes of infected patients along the disease course, and a shift from the TH-1 towards the TH-0/TH-2 phenotypes (with subsequent IL-10 release) has been hypothesized to underly AIDS progression. In this study the serum IL-10 levels found in 30 HIV-negative controls and in 65 HIV-positive patients, untreated with AZT and negative for HBsAg and HCV-Ab have been compared, using a commercial, competitive ELISA method based on a polyclonal anti-IL-10 serum. With this test, HIV-positive sera showed IL-10 levels significantly higher than those found in the controls. In addition the IL-10 levels progressively increased in the subsequent CDC stages, without further changes from the stage III to the stage IV. Accordingly, patients evaluated two times in CDC stage II with a time interval of at least one year, showed significant IL-10 increases, even more pronounced when the same patients passed from CDC stage II to stage III. Furthermore, a significant, negative correlation was observed between the circulating IL-10 levels and the patients' CD4/CD8 ratios. These data may be important from a clinical point of view since IL-10 monitoring could be considered as a surrogate marker for evaluating the disease progression. In addition, several immunological abnormalities present in HIV positive patients, such as the monocyte/macrophage impairment and the hypergammaglobulinemia could be related to the enhanced IL-10 expression.

AB - HIV-1 infection and the HIV gpl20 have been shown to induce an IL-10 increase in cultured peripheral blood mononuclear cells. Furthermore, the expression of this cytokine has been reported to increase in lymphnodes of infected patients along the disease course, and a shift from the TH-1 towards the TH-0/TH-2 phenotypes (with subsequent IL-10 release) has been hypothesized to underly AIDS progression. In this study the serum IL-10 levels found in 30 HIV-negative controls and in 65 HIV-positive patients, untreated with AZT and negative for HBsAg and HCV-Ab have been compared, using a commercial, competitive ELISA method based on a polyclonal anti-IL-10 serum. With this test, HIV-positive sera showed IL-10 levels significantly higher than those found in the controls. In addition the IL-10 levels progressively increased in the subsequent CDC stages, without further changes from the stage III to the stage IV. Accordingly, patients evaluated two times in CDC stage II with a time interval of at least one year, showed significant IL-10 increases, even more pronounced when the same patients passed from CDC stage II to stage III. Furthermore, a significant, negative correlation was observed between the circulating IL-10 levels and the patients' CD4/CD8 ratios. These data may be important from a clinical point of view since IL-10 monitoring could be considered as a surrogate marker for evaluating the disease progression. In addition, several immunological abnormalities present in HIV positive patients, such as the monocyte/macrophage impairment and the hypergammaglobulinemia could be related to the enhanced IL-10 expression.

KW - CDC stages

KW - HIV

KW - IL-10

KW - serum

KW - TH-0

KW - TH-1

KW - TH-2

UR - http://www.scopus.com/inward/record.url?scp=0027999682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027999682&partnerID=8YFLogxK

M3 - Article

C2 - 7863812

AN - SCOPUS:0027999682

VL - 8

SP - 48

EP - 52

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 2

ER -